Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields longer progression-free survival (PFS) than brentuximab vedotin with doxorubicin,
Immunotherapy improves survival in people with advanced Hodgkin lymphoma, study shows
An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial.
Nivolumab Bests Brentuximab Vedotin in Advanced Hodgkin Lymphoma
Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.
Groundbreaking details frokm URMC's new Hodgkins Lymphoma study
URMC shared new details about its new study into Hodgkins Lymphoma. Zuckerberg sacks staff on six-figure salaries for abusing office’s food delivery scheme All-WNBA First and Second Teams are announced,
92% Survival Rate: Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma
Immunotherapy has set a new standard in treating Hodgkin lymphoma, showing a 92% survival rate and fewer long-term side effects, with FDA approval anticipated soon. A new treatment that activates the
1h
Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...
BioSpace
7h
BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study
Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...
12d
on MSN
‘Amazing’ new lung cancer treatment 40% more effective than standard amid ‘golden age’ of cancer research
A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...
Cancer Therapy Advisor
7h
Data Support Induction Chemo as Standard Care for Locally Advanced Cervical Cancer
Short-course induction chemotherapy prior to chemoradiotherapy should be considered a standard of care, according to ...
Medscape
11h
Induction Chemotherapy Followed by Chemoradiotherapy Improves Survival in Advanced Cervical Cancer
Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...
Cure Today
1d
Avastin Regimen Versus Monitoring May Be Beneficial in Cholangiocarcinoma
Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active ...
13d
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaCohort A Data ...
Medscape
9d
Durvalumab Enhances Survival After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...
Targeted Oncology
2d
IMforte Shows Benefits of Lurbinectedin/Atezolizumab in ES-SCLC
A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...
FiercePharma
2d
Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback